KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals’ focus on protease inhibitors and its upcoming EKTERLY presentation signal promising biotech innovation amid market volatility.

KalVista Pharmaceuticals sees a major boost with EKTERLY’s Japan approval—yet investors face volatility, a negative P/E, and high valuation risks. Read the full story.

KalVista Pharmaceuticals: Needham‑rated biotech focusing on protease inhibitors, promising unmet‑needs pipeline, and strong investor confidence in its growth potential.

KalVista’s FDA‑approved oral drug Ekterly gives hereditary angioedema patients a fast, self‑administered break‑out therapy, positioning the company to capture rising global demand amid intensifying competition.

KalVista Pharmaceuticals, Inc. is a beacon of innovation and hope in the biotechnology sector, dedicated to developing small molecule protease inhibitors to treat diseases with significant unmet needs.